Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15– 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable EORTC experience, the Italian Group on Rare Tumors star...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Armando, Romanini, Antonella, Rosso, Alberto, Frustaci, Sergio, Comandone, Alessandro, Apice, Gaetano, De Toma, Domenico, Dogliotti, Luigi, Lionetto, Rita, Dani, Carla, Bruzzi, Paolo, Piolini, Marco, Bergnolo, Paola, Verusio, Claudio
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1999
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395431/
https://www.ncbi.nlm.nih.gov/pubmed/18521282
http://dx.doi.org/10.1080/13577149977613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395431/
https://www.ncbi.nlm.nih.gov/pubmed/18521282
http://dx.doi.org/10.1080/13577149977613

Ejemplares similares